BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Stem cell
,
Early pregnancy factor
,
Lovastatin
,
rs2476601
,
MDM2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
GSK256066
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Bronchus epithelial BEAS-2B cells with temporal treatment of GS-5759 or indacaterol and GSK256066
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.
Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the huma…
In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable fo…
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an…
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seaso…
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasona…
Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ